
The competition regulator in Britain has stated that the acquisition of Thales’ signaling business by Hitachi, which costs 1.7 billion euros ($1.8 billion), has the potential to increase the expenses associated with upgrading the country’s rail network. To address this issue, the regulator has requested that the companies provide a response.
The Competition and Markets Authority (CMA) identified Hitachi Rail and Thales SA’s Ground Transportation business as major suppliers of railway signaling systems, along with Siemens and Alstom, for both mainline and urban networks.
Read more: Hitachi-Thales Deal Referred To UK Antitrust Regulator
“We have provisionally found that, should the merger go ahead, it would reduce the number of signaling suppliers in what is already a highly concentrated industry, and the resulting loss of competition could leave transport networks and passengers worse off,” the CMA said on Thursday, reported Reuters.
“We will now consult on our findings and on how Hitachi and Thales might address our concerns, in a way that protects passengers and delivers the government’s objective for a more reliable, efficient and modern railway.”
Hitachi Rail expressed their disappointment with the CMA’s provisional findings and stated that they will carefully assess how to address the concerns raised.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas